Prelude Therapeutics Reports Pricing Of Public Offering For Total Gross Proceeds Of $100M
Portfolio Pulse from Benzinga Newsdesk
Prelude Therapeutics announced the pricing of its public offering, consisting of 3,048,522 voting common stock shares, 1,448,222 non-voting common stock shares, and pre-funded warrants for up to 12,895,256 common stock shares. The total gross proceeds are expected to be $100 million.
May 18, 2023 | 11:06 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Prelude Therapeutics' public offering is expected to raise $100 million in gross proceeds, potentially impacting the stock price.
The public offering will raise $100 million in gross proceeds for Prelude Therapeutics. This could impact the stock price as the market reacts to the news and the increased number of shares available. However, the short-term impact is uncertain, as it depends on investor sentiment and market conditions.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100